Introduction
Halofantrine (HF) is an effective treatment for chloroquine-resistant strains of Plasmodium falciparum [1, 2] . Although expensive in Africa, HF is being employed increasingly in private clinics to treat chloroquine-resistant falciparum malaria. In severe malaria, the combination of quinine and HF might be clinically superior to quinine alone because HF, but not quinine, significantly reduces the viability of circulating ring-stage parasites [3] . The absence of a parenteral formulation would complicate drug administration in severe disease, although the suspension could be given by nasogastric tube. Both chloroquine [4] and mefloquine [5] have been administered successfully by this route to patients with severe malaria. However, plasma concentrations of HF following oral dosage vary considerably in healthy Caucasian adults [6] and in adult Thai with malaria, which may contribute to drug failure [7] . HF produces a lengthening of the ECG QT-interval [8] , which is apparently dose-related [9] , and may predispose to ventricular arrhythmias. We have studied the pharmacokinetics of orally administered HF in uncomplicated and severe paediatric malaria to assess the potential for this drug as treatment for severe falciparum malaria.
Methods
Two consecutive studies were conducted, in children with non-severe, and with severe malaria. Approval for the study was Dosing and sampling Patients were given HF (nonmicronised oral suspension; 8 mg base kg-' body weight) 6 hourly for three doses; food and water were unrestricted. Blood (2 ml), for the measurement of plasma HF, was drawn through the cannula pre-dose, and at 3, 6, 9, 12, 15, 24, 36, 48 and 72 h after the first dose. Blood was centrifuged (1000 g for 10 min) within 1 h and plasma was stored at -70°C until transferred to Nairobi (on dry ice) for analysis. Plasma HF and HFm were estimated by the method of Mberu et al. [11] .
Children with severe malaria Patients and clinical care Children admitted to Kilifi District Hospital with a primary diagnosis of malaria were recruited if they were unable to drink from a cup, unable to sit unsupported (prostrate) [10] and if written consent was available. Patients were excluded if there was concurrent disease and criteria for exit were as described for the non-severe group. Patients were nursed in the KEMRI Clinical Research Ward, where they were examined at least 12 hourly by a physician until discharge. Teflon® cannulae were inserted into veins of both arms (one for i.v. fluids and drugs; one for sampling). A nasogastric tube was inserted; correct placement was determined by testing aspirate pH (Litmus paper), and by auscultation during air injection. Patients were observed closely for vomiting. Dosing and sampling An intravenous loading dose of quinine (20 mg kg-l) was given, followed by nine doses of 10 mg kg-" at 12 hourly intervals, as described elsewhere [12] . HF (non-micronised suspension: 8 mg base kg-' body weight; 6 hourly; three doses in total) was given by the nasogastric tube starting at the same time as the quinine. The nasogastric tube was flushed with water (10 ml) after each dose and then spigoted. Blood (2 ml) was drawn from the sampling cannula before treatment at the following times: 1, 2, 3, 4, 5, 6, 9, 12, 15, 24, 48, 72, 86 and 120 h. Aliquots of whole blood (100 ,ul in duplicate) were transferred by positive displacement pipette to filter paper strips for quinine assay [13] ; the rest of the blood samples were then centrifuged (1000 g; 10 min). Plasma (200 ,ul in duplicate) was transferred onto filter paper strips, which were stored at room temperature out of sunlight. Plasma HF and HFm concentrations were measured as before [11] .
In vitro chemosensitivity tests
The in vitro chemosensitivity to HF of 21 isolates of P. falciparum from the study area was measured by the Rieckman micro test [14] . For each test, seven wells of a 96-well microculture plate (Sterilin, UK) were loaded with drug solution (25 Jl in culture medium) immediately before inoculation with parasitised blood. All other test conditions were as previously described [1] .
Pharmacokinetic and statistical analyses
Peak plasma HF and HFm concentrations (Cmax) and the corresponding times (tmax) were noted directly from the data. The. elimination rate constant (,X) was calculated by linear regression of the terminal portion of the log plasma drug concentration-time curve (4-5 data points). The elimination half-life (t, 2, ) was estimated from ln2/XZ. AUC values were calculated by a combination of the linear trapezoidal method (rising concentrations) and the logarithmic trapezoidal method (falling concentrations), followed by extrapolation to infinity using Clast/Xz. 1-F [15, 16] , the population of parasites tested at Kilifi is regarded as essentially sensitive. dose was 20.1 + 3.3 ,ug ml-', and after the second dose it was 17.1 ± 2.1 gg ml-'.
Discussion
Quinine is the treatment of choice for severe malaria in Africa while parasites remain sensitive to the drug. However, even with optimal care, the mortality rate in severe malaria treated with quinine is 10 to 15% [10, 17] , which has stimulated the search for improved therapy. The observation that HF rapidly reduces the viability of P. falciparum ring-forms [3] suggested a possible role for HF in the treatment of severe malaria, despite the lack of a parenteral dosage form. However, clinical trial of quinine plus HF in severe malaria would have been premature without definition of the relative bioavailability of HF when administered by nasogastric tube, which was the rationale for this study.
In the children recruited from outpatients with uncomplicated disease, drug disposition was variable, as reported by others, although HF and HFm were measurable in all cases and at all sampling times. In these patients, the IC99 for HF (38 nmol 1-0.019 jig ml-') was exceeded in all patients for at least 48 h.
The pharmacokinetic parameters for both drug and metabolite were similar to those reported by Karb- wang et al. [7] , with the exception of the elimination half-life (t,l2,9) for HF which was considerably shorter in our study than the value (> 100 h) reported for Thai adults with non-severe malaria. The t,2,, of HFm could not be determined accurately in the present study because the sampling period was too short. HF disposition after adminstration by nasogastric tube to patients with severe malaria was much more variable than in the non-severe group; in the most extreme case neither HF nor HFm could be detected at any time point up to 120 h. All children with severe malaria received standard quinine therapy in addition to HF, and achieved adequate plasma drug concentrations [12] . Since all these children were cured, it must be assumed that quinine was the effective treatment where HF was undetectable, and that reliance of HF alone would have had serious, possibly fatal, consequences.
The relative bioavailability of HF is a function of food intake and type; fatty food increases HF absorption [6] . Our results may also reflect the effect of clinical malaria on appetite. Children with uncomplicated malaria are often anorectic, but prostrate children cannot eat, drink or breast-feed at all. Further, patients with severe malaria are relatively immobile, and subject to malabsorption (including drug malabsorption) which may be due to changes in small bowel blood flow [18] . Thus, several factors may have contributed to the variability in plasma HF and HFm concentrations in our study patients. We consider it likely that the differences in some estimated pharmacokinetic parameters between our study subjects reflect disease severity, although it is possible that they may have resulted from concomitant quinine (QN) treatment in the severely ill patients. However, no QN-HF drug interaction has been reported of which we are aware. Additionally, QN does not interfere with the h.p.l.c. assay of HF and HFm [11] .
HF is being used increasingly in Africa as a treatment for chloroquine-resistant malaria, particularly in private clinics. The results of this study emphasise the potential dangers of the borderline case; progression from non-severe to severe malaria is often very rapid, occurring over a few hours. Although our study involved children who were severely ill, they were not in coma and oral medication could have been considered an appropriate option under some circumstances.
The therapeutic ranges of HF and HFm have not been defined. In vitro tests of parasite chemosensitivity, as recorded in this study, remain essential tools for assessing temporal and geographical trends, but are of limited value in estimating in vivo efficacy. One reason for this is the difference in protein concentration between plasma and culture medium, which produces different concentrations of unbound drug; the degree of plasma protein binding of HF and HFm is not known. Similarly, although the QT prolongation produced by HF is thought to be concentration-dependent [9] , there are insufficient data to estimate a toxic threshold. The one cardiac death which has been linked unequivocally to HF occurred in a patient with plasma HF and HFm concentrations of 0.31 and 0.18 gg ml-', respectively [8] ; concentrations which are well within the ranges encountered during treatment without obvious toxicity.
HF remains a significant addition to a diminishing range of effective antimalarial drugs. However, the use of oral HF in severe malaria remains unproven; the negligible absorption in some patients is of considerable concern, and suggests that monotherapy with HF is inappropriate.
